Doma Holdings Inc. (NYSE:DOMA – Get Free Report) saw a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 96,300 shares, a drop of 7.8% from the August 31st total of 104,500 shares. Approximately 1.6% of the company’s shares are sold short. Based on an average daily trading volume, of 19,400 shares, the days-to-cover ratio is currently 5.0 days.
Hedge Funds Weigh In On Doma
An institutional investor recently raised its position in Doma stock. Renaissance Technologies LLC grew its stake in shares of Doma Holdings Inc. (NYSE:DOMA – Free Report) by 21.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 54,407 shares of the company’s stock after purchasing an additional 9,600 shares during the quarter. Renaissance Technologies LLC owned approximately 0.39% of Doma worth $330,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 20.67% of the company’s stock.
Doma Price Performance
Shares of Doma stock remained flat at $6.28 during trading on Tuesday. Doma has a 52-week low of $3.90 and a 52-week high of $6.29. The stock’s 50-day moving average is $6.08 and its 200-day moving average is $5.92. The stock has a market cap of $88.00 million, a price-to-earnings ratio of -0.82 and a beta of 1.58.
About Doma
Doma Holdings Inc issues residential and commercial title insurance for purchase and refinance transactions in the United States. It operates through two segments, Underwriting; and Corporate and Other. The company offers title insurance underwriting, including policies referred to through its third-party agents' channel; and other insurance services for the residential real estate market.
Further Reading
- Five stocks we like better than Doma
- 3 Monster Growth Stocks to Buy Now
- Why Lennar Stock Could Be the Best Play in the Housing Market
- What Are the U.K. Market Holidays? How to Invest and Trade
- 2 Energy Stocks Fueling the AI Datacenter Boom
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Doma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doma and related companies with MarketBeat.com's FREE daily email newsletter.